• Naomi Pearce

Pearce IP BioBlast: w/e 01 January 2021

Significant biosimilar activities this week include:

  • 27 Dec 20, CN: Innovent announced China's NMPA has approved Byvasda® (biosimilar bevacizumab) for the additional indication of adult recurrent glioblastoma.

  • 30 Dec 20: Alvotech announced it has broken ground on the extension to its high-tech centre in Reykjavik. The extension will house biosimilar development, drug refills, offices and warehouses, and is expected to be completed by the end of 2022.

Biosimilars Bulletin 
Search by tags

© 2019 Pearce IP | Australia

  • LinkedIn Social Icon